Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.34 |
| ▸ | LPL | P06858 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | HNF4A | P41235 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504886 | 0.91 | LIPG (0.40) | HIF1ATSHRHSD17B10LIPGLPL | |
| SCHEMBL20505519 | 0.87 | HIF1A (0.35) | HIF1ATSHRHSD17B10LIPGLPL | |
| SCHEMBL20504858 | 0.86 | ROCK1 (0.38) | HIF1ATSHRHSD17B10LIPGLPL | |
| SCHEMBL20505549 | 0.86 | AAK1 (0.39) | HIF1ATSHRHSD17B10LIPGDGAT1 | |
| SCHEMBL22408147 | 0.80 | LIPG (0.36) | HIF1ALIPGLPLGSK3AGSK3B | |
| SCHEMBL22407974 | 0.80 | ROCK1 (0.43) | HIF1ALIPGLPLDGAT1GSK3A | |
| SCHEMBL20504940 | 0.80 | LIPG (0.40) | LIPGLPL | |
| SCHEMBL20564345 | 0.78 | HIF1A (0.38) | HIF1ATSHRDGAT1GSK3AGSK3B | |
| SCHEMBL16898733 | 0.77 | HIF1A (0.44) | HIF1ATSHRHSD17B10LIPGLPL | |
| SCHEMBL20562145 | 0.77 | GAA (0.38) | HIF1ATSHRDGAT1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-3377483-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | HIF1A 1633/4885TSHR 325/4885HSD17B10 1375/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | HIF1A 1633/4885TSHR 325/4885HSD17B10 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.